Immunai

Company profile

About Immunai

Immunai is a precision medicine company that leverages artificial intelligence and single-cell multiomics to decode the immune system and accelerate therapeutic development. The company has built AMICA, the world's largest immune-focused, harmonized single-cell database, comprising data from over 5,000 studies, 350+ single-cell studies, 800+ cell types, and 300,000+ patient samples. Immunai's integrated end-to-end platform combines high-quality multiomic data generation, advanced machine learning through their ImmunoDynamics Engine (IDE), and functional genomics validation to deliver actionable insights for drug discovery and development. The company offers three core solutions: Target Discovery to identify novel high-impact targets linked to disease, Preclinical Evaluation to prioritize promising drug candidates, and Clinical Trial Optimization to identify patient subgroups and treatment strategies that maximize trial success. Immunai partners with leading biopharmaceutical companies including AstraZeneca and Teva on projects ranging from inflammatory bowel disease target discovery to vitiligo disease mechanism research and oncology clinical trial optimization. The company's multidisciplinary team combines expertise in immunology, computational biology, machine learning, and drug development to transform complex therapeutic questions into clear, data-driven recommendations that help pharma companies make smarter choices, reduce risks, and bring better therapies to patients faster.

Company description · Immunai official website